|CRISPR-Cas9 genome editing utilizing chemically synthesized RNA|
Kaizhang He, Eldon Chou, Amanda Haas, Žaklina Strezoska, Melissa L. Kelley, and Anja van Brabant Smith Dharmacon, part of GE Healthcare, 2650 Crescent Drive, Lafayette, CO 80026, USA
CRISPR-Cas9 gene editing using synthetic crRNA:tracrRNA or sgRNA is highly efficient and easy to use. Synthetic crRNA:tracrRNA is uniquely suited to in vitro and in vivo applications, in particular, DNA-free approach with Cas9 mRNA. Chemical synthesis of guide RNAs allows accurate and rapid production of arrayed crRNA libraries for high-confidence, loss-of-function screens.
|Deep Phenotyping - Harnessing Data Richness for Unsupervised High-Content Analysis|
Huang Dong, Wang Yi, Maciej Hermanowicz, Ke Yiping, Maja Choma, Lee Kee Khoon, Frederic Bard
Recognising the key challenges, we develop an end-to-end computational framework for HCA dubbed “Deep Phenotyping” that perform unsupervised analysis to leverage on the data richness for the discovery of unknown sub-phenotypes with minimal labeling cost.
|Assessment of the Anti-angiogenic Effect of VEGFR2 siRNA in Clonetics™ HUVEC using the Lonza 4D-Nucleofector™ System|
Srinivasan Kokatam1 , Kanchan Tiwari1 , Jenny Schroeder2 , Andrea Toell2 , Lubna Hussain3, Preeti Kapoor1
In the current study we have used siRNA targeting VEGFR2 as an example to study knockdown of VEGFR2 and subsequent inhibition of tube formation by HUVECs on Growth Factor Reduced Matrigel™ in a 96-well plate format. The same strategy can be used for screening and validating siRNA based inhibitors of the angiogenic process in vitro and thus could be of utility in anti-cancer screening strategies.
|Targeting Acute Pancreatitis by Small Molecule Inhibitors of Cyclophilin D|
M. Awais, E. Shore, R. Gibson, N. Kershaw, D. Latawiec, S. Pandalaneni, M.A. Javed, L. Wen, D.N. Criddle, N. Berry, L-Y. Lian, P. O’Neill, R. Sutton
Cyclophilin D (CypD) promotes opening of the mitochondrial permeability transition pore, a major contributor to acute pancreatitis. We are developing small molecule inhibitors of CypD as a possible treatment for AP and other conditions where the MPTP plays a role.
|The Pathogen Box: A Catalyst for Neglected Disease Drug Discovery|
Benoît Laleu*, Thomas Spangenberg, Wesley Van Voorhis, Angelique Doy, Dylan Pillai, Andreas Verras, Joie Garfunkle, Jeremy Burrows, Timothy Wells, Paul Willis
Modelled after the Malaria Box, the Pathogen Box contains ~400 diverse drug-like molecules active against neglected diseases of interest such as Chagas disease, cryptosporidiosis, hookworm, sleeping sickness, leishmaniasis, lymphatic filariasis, malaria, onchocerciasis, schistosomiasis, trichuriasis, tuberculosis.
|Analysis of Terpenes Using Gas Chromatography with Vacuum Ultraviolet |
Changling Qiu, Jonathan Smuts, Phillip Walsh, and Kevin A. Schug
The VUV absorption spectra for different terpenes were distinctive and differentiable. GC-VUV demonstrated the capabilities for qualitative and quantitative analysis of terpenes in turpertine mixtures. Chromatographic coeluting signals can be deconvolved by the VUV data analysis software.
|Mobility of Aeroallergens in Home: Effect of Location of Air Sampling and Implication for Evaluation of Patient Exposure|
Julian Gordon1, Paul Detjen, Andrea Wachter & Prasanthi Gandhi1
The Inspirotec sampler permitted the easy testing of multiple locations within a household. Air sampling simultaneously at 12 locations by other technologies would have been technically challenging. These were run by an untrained operator.
|Selective Debenzylation of N-Benzyloxypyrazinones in Flow|
Anh Hung MAI - Cedrick VERYSER - Wim DE BORGGRAEVE
Selective and reproducible debenzylation of benzyloxypyrazinones by using catalytic transfer hydrogenation in flow chemistry to yield N-hydroxypyrazinones. The flow methodology enabled us to avoid overreduction of the compounds to pyrazin-2(1H)-ones.
|Addressing False Positive Variants Arising from Pseudogenes|
Risha Govind1,2, Sam Wilkinson1,3, Nicola Whiffin1,2, Shibu John1,2, Rachel J. Buchan1,2, Elizabeth Edwards1,2, Deborah J. Morris-Rosendahl1,3, James S. Ware1,2, P.J. Barton1,2, Stuart A. Cook1,2
Clinical genetic testing has been transformed in recent years by the introduction of Next-Generation Sequencing (NGS).
|The Challenges of Genetic Testing in Patients Diagnosed with Breast Cancer; The Kent Oncology Centre Experience|
Christos Mikropoulos1,2, Aaron Davies 1, Charlotte Abson1, Gill Sadler1, Gemma McCormick1, Questa Karlsson2, Julia Hall2
In this study we explore retrospective data to determine strategies for optimizing the genetic referral pathways for breast cancer.
|<<|| 1 2 3 4 5 6 7 || >>|
|Showing Results 1 - 10 of 357||